MYOV Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (9 kov. 2023 @ 23:01):

Stats
Šios dienos apimtis	2.26M
Vidutinė apimtis	1.09M
Rinkos kapitalizacija	2.62B
EPS	$0 ( 2023-07-25 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-14.05
ATR14	$0.0590 (0.22%)

Insider Trading

Date	Person	Action	Amount	type
2023-03-10	Valente Nancy	Sell	3 673	Common Shares
2023-03-10	Valente Nancy	Sell	36 892	Stock Options (Right to Buy)
2023-03-10	Potter Myrtle S	Sell	3 673	Common Shares
2023-03-10	Potter Myrtle S	Sell	45 000	Stock Options (Right to Buy)
2023-03-10	Potter Myrtle S	Sell	58 608	Stock Options (Right to Buy)

INSIDER POWER
71.95
Last 100 transactions
Buy: 52 768 183 \| Sell: 8 648 674

Tūris Koreliacija

Ilgas: 0.03 (neutral)

Trumpas: -0.75 (moderate negative)

Signal:(61.005) Neutral

Myovant Sciences Ltd Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Myovant Sciences Ltd Koreliacija - Valiuta/Žaliavos

-0.13
( neutral )

-0.18
( neutral )

0.42
( neutral )

0.19
( neutral )

0.71
( moderate )

-0.04
( neutral )

Myovant Sciences Ltd Finansinės ataskaitos

Annual	2022
Pajamos:	$230.97M
Bruto pelnas:	$179.42M (77.68 %)
EPS:	$-2.22

FY	2022
Pajamos:	$230.97M
Bruto pelnas:	$179.42M (77.68 %)
EPS:	$-2.22

FY	2021
Pajamos:	$59.32M
Bruto pelnas:	$57.35M (96.69 %)
EPS:	$-2.83

FY	2020
Pajamos:	$0.00
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-3.37

Financial Reports:

No articles found.

Myovant Sciences Ltd

Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It is also developing MVT-602, an oligopeptide kisspeptin agonist, which is in Phase II clinical trial for the treatment of female infertility as part of assisted reproduction. Myovant Sciences Ltd. has collaboration with Pfizer Inc. to develop and commercialize relugolix in oncology and women's health. The company was formerly known as Roivant Endocrinology Ltd. and changed its name to Myovant Sciences Ltd. in May 2016. The company was incorporated in 2016 and is based in London, the United Kingdom. Myovant Sciences Ltd. is a subsidiary of Sumitovant Biopharma Ltd.